Priyanka Singh1, Sanjay Kumar Bhadada1, Divya Dahiya2, Uma Nahar Saikia3, Ashutosh Kumar Arya1, Naresh Sachdeva1, Jyotdeep Kaur4, Arunanshu Behera2, Maria Luisa Brandi5, Sudhaker Dhanwada Rao6. 1. Department of Endocrinology, Post Graduate Institute of Medical Education and Research (PGIMER), Chandigarh, 160012, India. 2. Department of General Surgery, PGIMER, Chandigarh, 160012, India. 3. Department of Histopathology, PGIMER, Chandigarh, 160012, India. 4. Department of Biochemistry, PGIMER, Chandigarh, 160012, India. 5. Department of Experimental and Clinical Biomedical Sciences, University of Florence, Florence 50121, Italy. 6. Bone and Mineral Research Laboratory, Henry Ford Hospital, Detroit, Michigan 48202, USA.
Abstract
CONTEXT: Glial cells missing 2 (GCM2), a zinc finger-transcription factor, is essentially required for the development of the parathyroid glands. OBJECTIVE: We sought to identify whether the epigenetic alterations in GCM2 transcription are involved in the pathogenesis of sporadic parathyroid adenoma. In addition, we examined the association between promoter methylation and histone modifications with disease indices. METHODS: Messenger RNA (mRNA) and protein expression of GCM2 were analyzed by reverse transcriptase-quantitative polymerase chain reaction (RT-qPCR) and immunohistochemistry in 33 adenomatous and 10 control parathyroid tissues. DNA methylation and histone methylation/acetylation of the GCM2 promoter were measured by bisulfite sequencing and chromatin immunoprecipitation-qPCR. Additionally, we investigated the role of epigenetic modifications on GCM2 and DNA methyltransferase 1 (DNMT1) expression in parathyroid (PTH)-C1 cells by treating with 5-aza-2'-deoxycytidine (DAC) and BRD4770 and assessed for GCM2 mRNA and DNMT1 protein levels. RESULTS: mRNA and protein expression of GCM2 were lower in sporadic adenomatous than in control parathyroid tissues. This reduction correlated with hypermethylation (P < .001) and higher H3K9me3 levels in the GCM2 promoter (P < .04) in adenomas. In PTH-C1 cells, DAC treatment resulted in increased GCM2 transcription and decreased DNMT1 protein expression, while cells treated with the BRD4770 showed reduced H3K9me3 levels but a nonsignificant change in GCM2 transcription. CONCLUSION: These findings suggest the concurrent association of promoter hypermethylation and higher H3K9me3 with the repression of GCM2 expression in parathyroid adenomas. Treatment with DAC restored GCM2 expression in PTH-C1 cells. Our results showed a possible epigenetic landscape in the tumorigenesis of parathyroid adenoma and also that DAC may be a promising avenue of research for parathyroid adenoma therapeutics.
CONTEXT: Glial cells missing 2 (GCM2), a zinc finger-transcription factor, is essentially required for the development of the parathyroid glands. OBJECTIVE: We sought to identify whether the epigenetic alterations in GCM2 transcription are involved in the pathogenesis of sporadic parathyroid adenoma. In addition, we examined the association between promoter methylation and histone modifications with disease indices. METHODS: Messenger RNA (mRNA) and protein expression of GCM2 were analyzed by reverse transcriptase-quantitative polymerase chain reaction (RT-qPCR) and immunohistochemistry in 33 adenomatous and 10 control parathyroid tissues. DNA methylation and histone methylation/acetylation of the GCM2 promoter were measured by bisulfite sequencing and chromatin immunoprecipitation-qPCR. Additionally, we investigated the role of epigenetic modifications on GCM2 and DNA methyltransferase 1 (DNMT1) expression in parathyroid (PTH)-C1 cells by treating with 5-aza-2'-deoxycytidine (DAC) and BRD4770 and assessed for GCM2 mRNA and DNMT1 protein levels. RESULTS: mRNA and protein expression of GCM2 were lower in sporadic adenomatous than in control parathyroid tissues. This reduction correlated with hypermethylation (P < .001) and higher H3K9me3 levels in the GCM2 promoter (P < .04) in adenomas. In PTH-C1 cells, DAC treatment resulted in increased GCM2 transcription and decreased DNMT1 protein expression, while cells treated with the BRD4770 showed reduced H3K9me3 levels but a nonsignificant change in GCM2 transcription. CONCLUSION: These findings suggest the concurrent association of promoter hypermethylation and higher H3K9me3 with the repression of GCM2 expression in parathyroid adenomas. Treatment with DAC restored GCM2 expression in PTH-C1 cells. Our results showed a possible epigenetic landscape in the tumorigenesis of parathyroid adenoma and also that DAC may be a promising avenue of research for parathyroid adenoma therapeutics.
Authors: Serge X Cohen; Martine Moulin; Oliver Schilling; Wolfram Meyer-Klaucke; Jörg Schreiber; Michael Wegner; Christoph W Müller Journal: FEBS Lett Date: 2002-09-25 Impact factor: 4.124
Authors: Athena Starlard-Davenport; Volodymyr P Tryndyak; Smitha R James; Adam R Karpf; John R Latendresse; Frederick A Beland; Igor P Pogribny Journal: Carcinogenesis Date: 2009-12-14 Impact factor: 4.944
Authors: Michael Mannstadt; Guylène Bertrand; Mihaela Muresan; Georges Weryha; Bruno Leheup; Sirish R Pulusani; Bernard Grandchamp; Harald Jüppner; Caroline Silve Journal: J Clin Endocrinol Metab Date: 2008-06-26 Impact factor: 5.958
Authors: Masahide Mizobuchi; Cynthia S Ritter; Irina Krits; Eduardo Slatopolsky; Gregorio Sicard; Alex J Brown Journal: J Bone Miner Res Date: 2009-07 Impact factor: 6.741
Authors: Bin Guan; James M Welch; Meghana Vemulapalli; Yulong Li; Hua Ling; Electron Kebebew; William F Simonds; Stephen J Marx; Sunita K Agarwal Journal: J Endocr Soc Date: 2017-03-23